ARCHIVES

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

This article is from The Cancer Letter archive.

Vol. 26 No. 12 | December 26, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Plans 3 Percent Across-The-Board Cut To Pool Funds For High Priorities In FY08.

September 21, 2007

Foundations: Lasker Awards honor Work In Nitric Oxide, HIB Vaccine

October 4, 1996

In Brief: Diane Fink Moves to ACS California Div.; Preisler Names Director Of Cancer Center In Cincinnati

February 10, 1989

After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

July 11, 2014

ASCO Proposes Principles For Future Debate on Medicaid

November 21, 2014

FDA Approves Taxotere And Gemzar; Sends Approvable Letter For Etopophos

May 24, 1996